Our top pick for
Palatin Technologies, Inc is a biotechnology business based in the US. Palatin Technologies shares (PTN) are listed on the NYSE MKT and all prices are listed in US Dollars. Palatin Technologies employs 20 staff and has a market cap (total outstanding shares value) of USD$95.4 million.
|52-week range||USD$0.36 - USD$0.83|
|50-day moving average||USD$0.4178|
|200-day moving average||USD$0.5051|
|Wall St. target price||USD$2.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.151|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Palatin Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Palatin Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Palatin Technologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Palatin Technologies shares trade at around 3x recent earnings.
Palatin Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$36 million.
The EBITDA is a measure of a Palatin Technologies's overall financial performance and is widely used to measure a its profitability.
|Operating margin TTM||9073.87%|
|Gross profit TTM||USD$-13,841,408|
|Return on assets TTM||-15.26%|
|Return on equity TTM||-25.26%|
|Market capitalisation||USD$95.4 million|
TTM: trailing 12 months
There are currently 7.7 million Palatin Technologies shares held short by investors – that's known as Palatin Technologies's "short interest". This figure is 8.5% down from 8.5 million last month.
There are a few different ways that this level of interest in shorting Palatin Technologies shares can be evaluated.
Palatin Technologies's "short interest ratio" (SIR) is the quantity of Palatin Technologies shares currently shorted divided by the average quantity of Palatin Technologies shares traded daily (recently around 861699.77703456). Palatin Technologies's SIR currently stands at 8.97. In other words for every 100,000 Palatin Technologies shares traded daily on the market, roughly 8970 shares are currently held short.
However Palatin Technologies's short interest can also be evaluated against the total number of Palatin Technologies shares, or, against the total number of tradable Palatin Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Palatin Technologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Palatin Technologies shares in existence, roughly 30 shares are currently held short) or 0.0341% of the tradable shares (for every 100,000 tradable Palatin Technologies shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Palatin Technologies.
Find out more about how you can short Palatin Technologies stock.
We're not expecting Palatin Technologies to pay a dividend over the next 12 months.
Palatin Technologies's shares were split on a 1:10 basis on 27 September 2010. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Palatin Technologies shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Palatin Technologies shares which in turn could have impacted Palatin Technologies's share price.
Over the last 12 months, Palatin Technologies's shares have ranged in value from as little as $0.36 up to $0.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Palatin Technologies's is 1.6477. This would suggest that Palatin Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.